Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), HCA Healthcare (HCA) and Cardiff Oncology (CRDF)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on UnitedHealth (UNH – Research Report), HCA Healthcare (HCA – Research Report) and Cardiff Oncology (CRDF – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
UnitedHealth (UNH)
In a report released today, Matthew Gillmor CFA from KeyBanc maintained a Buy rating on UnitedHealth, with a price target of $400.00. The company’s shares closed last Tuesday at $282.70.
According to TipRanks.com, CFA has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for UnitedHealth with a $396.71 average price target, representing a 34.9% upside. In a report released yesterday, TipRanks – OpenAI also upgraded the stock to Buy with a $399.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
HCA Healthcare (HCA)
In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on HCA Healthcare, with a price target of $551.00. The company’s shares closed last Tuesday at $505.84.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for HCA Healthcare with a $505.83 average price target, representing a 0.2% upside. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $541.00 price target.
Cardiff Oncology (CRDF)
TD Cowen analyst Marc Frahm maintained a Buy rating on Cardiff Oncology yesterday. The company’s shares closed last Tuesday at $2.00.
According to TipRanks.com, Frahm is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cardiff Oncology with a $13.67 average price target, a 560.4% upside from current levels. In a report released yesterday, Craig-Hallum also maintained a Buy rating on the stock.
